Patents Assigned to UCB Biopharma SRL
  • Patent number: 11554122
    Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF a activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: January 17, 2023
    Assignees: UCB BIOPHARMA SRL, SANOFI
    Inventors: James Andrew Johnson, Ellen Olivia Gallimore, Mengyang Xuan
  • Patent number: 11524997
    Abstract: The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: December 13, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Gareth Charles Glyndwr Davies, Scott John Roberts
  • Patent number: 11518803
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: December 6, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Bon, Joanne Elizabeth Compson, Kate Louise Dixon, Carl Brendan Doyle, Mark Ellis, Maria Margarida Gouveia Sancho, Raymond Anthony Jupp, Lara Kevorkian, Daniel John Lightwood, Diane Marshall, Andrew Charles Payne, Joseph Michael David Rastrick, Monika-Sarah Schulze, Alison Turner, Kerry Louise Tyson
  • Patent number: 11498941
    Abstract: The present invention is in the field of purification and protein purification in particular. The invention provides improved techniques for the industrial-scale purification of proteins and other biomolecules. More specifically, it relates to a process for the purification of a compound of interest, such as a protein, preferably an antibody or an antibody fragment using a chromatography step, preferably a semi-continuous chromatography step.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: November 15, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventor: Michael Harry Rose
  • Patent number: 11492396
    Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 8, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
  • Patent number: 11472879
    Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: October 18, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
  • Patent number: 11472794
    Abstract: A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 18, 2022
    Assignee: UCB Biopharma SRL
    Inventors: Gareth Neil Brace, Rose Elizabeth Bardell-Cox, Gregory Foulkes, James Richard Frost, Helen Tracey Horsley, Elizabeth Pearl Jones, Fabien Claude Lecomte, James Thomas Reuberson, Monika-Sarah Elizabeth Dorothea Schulze, Richard David Taylor, Wei Tsung Yau, Zhaoning Zhu
  • Patent number: 11466076
    Abstract: The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: October 11, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Sam Philip Heywood
  • Patent number: 11466324
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: October 11, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Fairfull Watt
  • Patent number: 11448655
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: September 20, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow
  • Patent number: 11427650
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: August 30, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Patent number: 11407835
    Abstract: The present invention relates to pharmaceutical compositions comprising an antibody or a fragment thereof suitable for freeze-drying (i.e. lyophilizing). The pharmaceutical compositions, which comprise an antibody or an antigen-binding fragment thereof; from 1% to 20% w/v sucrose; an amino acid or a mixture of amino acids; and surfactant, are provided as pharmaceutical compositions for freeze-drying; as freeze-dried (i.e. lyophilized) compositions which can be reconstituted into a solvent at the time of use or as reconstituted liquid formulations ready for administration.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: August 9, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Andrew Jeffrey Yates, Jan Ivo Massant
  • Patent number: 11401349
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, nindependently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V1 and V2, in particular where a disulphide bond is present.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 2, 2022
    Assignee: UCB Biopharma SRL
    Inventors: Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 11384136
    Abstract: The present disclosure relates to a method for the manufacture of recombinant antibody molecules comprising culturing a host cell sample transformed with an expression vector encoding a recombinant antibody molecule; adding an extraction buffer to the sample; and subjecting the sample to a heat treatment step; wherein the pH of the sample is detected after addition of the extraction buffer, and optionally adjusted, to ensure that the pH of the sample is 6 to 9 prior to the heat treatment step.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: July 12, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Jean-Pascal Pierre Bilgischer, Philip Jonathan Bassett, Mark Robert Pearce-Higgins, Andrew John Kenny
  • Patent number: 11345760
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH—CH1—X—V1; and b) a polypeptide chain of formula (II): VL-CL-Y—V2 and pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 31, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 11341639
    Abstract: A machine-based learning method estimates a probability of bone fractures in a 3D image, more specifically vertebral fractures. The method and system utilizing such method utilize a data-driven computational model to learn 3D image features for classifying vertebra fractures. A three-dimensional medical image analysis system for predicting a presence of a vertebral fracture in a subject includes a 3D image processor for receiving and processing 3D image data of a 3D image of the subject, producing two or more sets of 3D voxels. Each of the sets of 3D voxels corresponds to an entirety of the 3D image and each of the sets of 3D voxels consists of equal 3D voxels of different dimensions. The system also includes a voxel classifier for assigning the 3D voxels one or more class probabilities each of the 3D voxels contains a fracture using a computational model, and a fracture probability estimator for estimating a probability of the presence of a vertebral fracture in the subject.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: May 24, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventor: Joeri Nicolaes
  • Patent number: 11315685
    Abstract: A method of building a machine learning pipeline for predicting the efficacy of anti-epilepsy drug treatment regimens is provided.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: April 26, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Kunal Malhotra, Sungtae An, Jimeng Sun, Myung Choi, Cynthia Dilley, Chris Clark, Joseph Robertson, Edward Han-Burgess
  • Patent number: 11292831
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: April 5, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Patrick Downey, Kerry Louise Tyson, Marco Kriek, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan, Peter Charles Elliott, Terence Seward Baker
  • Patent number: 11286312
    Abstract: The present invention relates to heterodimerically-tethered bispecific protein complexes (according to the general formula of A-X:Y-B) and libraries/multiplexes thereof for use in research and therapy and in particular an in vitro/ex vivo method of detecting synergistic biological function of otherwise unknown pairs of targets.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: March 29, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Pallavi Bhatta, Laura Starkie, Michael John Wright
  • Patent number: 11261242
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Patrick Downey, Terence Seward Baker, Kerry Louise Tyson, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan